This transcript has been edited for clarity.
At the 2021 Endocrine Society meeting, an update to the STEP trials was presented. For those of you who don't remember what the STEP trials are, they are four different trials looking at the benefits of semaglutide for weight loss in people with and without diabetes. The trial included people who were 18 years or older with a BMI ≥ 30 kg/m2 in the absence of a weight-related preexisting condition, or BMI ≥ 27 kg/m2 if they did have a preexisting condition.
Breaking Down the Trials
STEP 1, which was recently published in The New England Journal of Medicine, looked at a dose of 2.4 mg semaglutide and lifestyle intervention in patients with obesity who didn't have diabetes. Many of my patients saw this study as a headline and many of them wanted to go on semaglutide immediately. They didn't realize that they'd already been on semaglutide, but just at the lower 1-mg dose that is currently FDA-approved for the treatment of type 2 diabetes.
STEP 2 is for [2.4 mg] semaglutide and lifestyle intervention in individuals with type 2 diabetes and obesity. STEP 3is also 2.4 mg semaglutide in conjunction with intensive behavioral therapy in adults with obesity. And
COMMENTARY
Updates on Semaglutide for Weight Loss, From ENDO 2021
Anne L. Peters, MD
DisclosuresApril 20, 2021
This transcript has been edited for clarity.
At the 2021 Endocrine Society meeting, an update to the STEP trials was presented. For those of you who don't remember what the STEP trials are, they are four different trials looking at the benefits of semaglutide for weight loss in people with and without diabetes. The trial included people who were 18 years or older with a BMI ≥ 30 kg/m2 in the absence of a weight-related preexisting condition, or BMI ≥ 27 kg/m2 if they did have a preexisting condition.
Breaking Down the Trials
STEP 1, which was recently published in The New England Journal of Medicine, looked at a dose of 2.4 mg semaglutide and lifestyle intervention in patients with obesity who didn't have diabetes. Many of my patients saw this study as a headline and many of them wanted to go on semaglutide immediately. They didn't realize that they'd already been on semaglutide, but just at the lower 1-mg dose that is currently FDA-approved for the treatment of type 2 diabetes.
STEP 2 is for [2.4 mg] semaglutide and lifestyle intervention in individuals with type 2 diabetes and obesity. STEP 3is also 2.4 mg semaglutide in conjunction with intensive behavioral therapy in adults with obesity. And
Medscape Diabetes © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters. Updates on Semaglutide for Weight Loss, From ENDO 2021 - Medscape - Apr 20, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Anne L. Peters, MD
Professor, Department of Clinical Medicine, Keck School of Medicine; Director, University of Southern California Westside Center for Diabetes, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Serve(d) on the advisory board for: Abbott Diabetes Care; Becton Dickinson; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Lexicon Pharmaceuticals, Inc.; Livongo; Medscape; Merck & Co., Inc.; Novo Nordisk; Omada Health; OptumHealth; sanofi; Zafgen
Received research support from: Dexcom; MannKind Corporation; Astra Zeneca
Serve(d) as a member of a speakers bureau for: Novo Nordisk